AG-1478 HCl (also known as Tyrphostin AG-1478) is a novel, potent and selective EGFR (epidermal growth factor receptor) inhibitor with IC50 of 3 nM in cell-free assays.

MTX-211 is a novel and potent dual inhibitor of EGFR and PI3K with the potential to be used for the treatment of cancer, in particular KRAS mutant colorectal cancer.

AZ7550 HCl, the hydrochloride salt of AZ-7550, is N-demethylated (one of the methyl groups is removed from the ethyl diamine side chain) and active metabolite of AZD9291 (Osimertinib), which is approved anticancer drug that inhibits IGF1R with an IC50 of 1.6 μM.

PF-06459988 (PF06459988) is an orally bioavailable, 3rd-generation, covalent/irreversible inhibitor of T790M-Containing EGFR Mutants with potential anticancer activity.

AZ7550 Mesylate (AZ-7550), the mesylate salt of AZ 7550, is an active metabolite of AZD-9291 (Osimertinib) by removing one of the methyl groups from the ethyl diamine side chain.

Falnidamol (formerly known as BIBX 1382) is a potent and selective inhibitor EGFR inhibitor with IC50 of 3 nM and potential anticancer activities; it displays > 1000-fold lower potency against ErbB2 (IC50 = 3.4 μM) and a range of other related tyrosine kinases (IC50 > 10 μM).

Icotinib HCl (formerly known as BPI-2009 HCl), the hydrochloride salt of Icotinib and an macrocyclic analog of erlotinib, is an orally bioavailable, potent and specific EGFR inhibitor with IC50 of 5 nM, including the EGFR, EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R).

BMS-690514 is a novel, potent and orally bioavailable inhibitor of EGFR [human epidermal growth factor receptor (HER) 1] and VEGFR (vascular endothelial growth factor receptors) with IC50s of 5, 20 and 60 nM for EGFR, HER 2 and HER 4, respectively.

PD153035 HCl (SU-5271; ZM-252868), the hydrochloride salt of PD153035 (also called PD-153035), is an ATP competitive EGFR inhibitor with potential antineoplastic activity.

CL-387785 (CL387785; WAY-EKI 785; EKI 785; EKI785) is a novel, potent, covalent / irreversible, and selective EGFR inhibitor with potential anticancer activity.